OLYSIO

Land: Neuseeland

Sprache: Englisch

Quelle: Medsafe (Medicines Safety Authority)

Wirkstoff:

Simeprevir sodium 154.4mg equivalent to simeprevir 150.0 mg

Verfügbar ab:

Janssen-Cilag (New Zealand) Ltd

INN (Internationale Bezeichnung):

Simeprevir sodium 154.4 mg (equivalent to simeprevir 150.0 mg)

Dosierung:

150 mg

Darreichungsform:

Capsule

Zusammensetzung:

Active: Simeprevir sodium 154.4mg equivalent to simeprevir 150.0 mg Excipient: Colloidal silicon dioxide Croscarmellose sodium Gelatin Lactose monohydrate Magnesium stearate Opacode black S-1-277002 Sodium laurilsulfate

Verschreibungstyp:

Prescription

Hergestellt von:

Janssen Pharmaceutica NV

Anwendungsgebiete:

Olysio is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 or genotype 4 infection, in combination with other medicinal products for the treatment of CHC infection.

Produktbesonderheiten:

Package - Contents - Shelf Life: Blister pack, PVC-PE-PVDC blister & Al push-through foil - 7 capsules - 24 months from date of manufacture stored at or below 30°C protect from light - Blister pack, PVC-PE-PVDC blister & Al push-through foil - 28 capsules - 24 months from date of manufacture stored at or below 30°C protect from light

Berechtigungsdatum:

2013-09-02